(Q47326952)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

review article

1 reference

title

De-novo and acquired resistance to immune checkpoint targeting (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Tony Mok

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

Michele W L Teng

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Ross A Soo

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

publication date

1 December 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

5 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

e731-e741

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

Enhancement of antitumor immunity by CTLA-4 blockade

5 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Bystander elimination of antigen loss variants in established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Neoantigen landscape dynamics during human melanoma-T cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

The host STING pathway at the interface of cancer and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

The epigenetic landscape of T cell exhaustion.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Innate and adaptive immune cells in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

The immune contexture in human tumours: impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Effective combinatorial immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Targeting cancer-derived adenosine: new therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

CANCER IMMUNOLOGY. The "cancer immunogram".

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Inhibitory effect of tumor cell-derived lactic acid on human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Microbiome and Anticancer Immunosurveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Is autoimmunity the Achilles' heel of cancer immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

Classifying Cancers Based on T-cell Infiltration and PD-L1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930607-1

7 January 2021

10.1016/S1470-2045(17)30607-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29208439%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference